# A Phase II Platform Study to Evaluate Treatment With Cemiplimab Monotherapy or Cemiplimab Plus Fianlimab or Other Novel Combinations in Patients With Colorectal

Source: https://onco.cc/trials/nct07058012/  
OnCo record `nct07058012` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of cemiplimab, fianlimab and REGN7075 in colorectal cancer, run by NSABP Foundation Inc, now recruiting.

## Summary

A Phase II Platform Study to Evaluate Treatment With Cemiplimab Monotherapy or Cemiplimab Plus Fianlimab or Other Novel Combinations in Patients With Colorectal Cancer With Minimal Residual Disease Following Definitive Surgery and Chemotherapy (EMPIRE) is a phase 2, interventional study registered as NCT07058012 by NSABP Foundation Inc, with a registry enrolment figure of 79 participants, started 2026-04-17 and due to reach its primary completion in 2029-04-17. Interventions recorded: Cemiplimab; cemiplimab plus fianlimab; cemiplimab + REGN7075; ctDNA testing. Conditions listed: Colo-rectal Cancer. Primary outcome: Clearance of cDNA. Colorectal eligibility wording from the registry: "* Patients must have confirmed histologic and pathologic stage II/III colon, stage II/III rectal, or oligometastatic stage IV colorectal adenocarcinoma (per AJCC 8th edition)". Sites: United States. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Also known as: EMPIRE
- Tags: ctgov-ingest; colorectal-deep-dive
- Registry id: NCT07058012
- Phase: 2
- Setting: A Phase II Platform Study to Evaluate Treatment With Cemiplimab Monotherapy or Cemiplimab Plus Fianlimab and Other Novel Combinations in Patients With Colorectal Cancer With Minimal Residual Disease Following Definitive Surgery and Chemotherapy
- Sponsor: NSABP Foundation Inc
- Enrolled: 79

## Sources

- ClinicalTrials.gov NCT07058012: https://clinicaltrials.gov/study/NCT07058012

## Connected records

- cancers: [Colon cancer (adenocarcinoma of the colon)](https://onco.cc/cancers/colon-cancer/), [Rectal cancer](https://onco.cc/cancers/rectal-cancer/)
- technologies: [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/), [MRD / molecular residual disease testing](https://onco.cc/technologies/mrd-testing/)
- drugs: [Cemiplimab](https://onco.cc/drugs/cemiplimab/), [Fianlimab](https://onco.cc/drugs/fianlimab/), [REGN7075](https://onco.cc/drugs/regn7075/)
- companies: [Regeneron](https://onco.cc/companies/regeneron/)
- terms: [Colorectal cancer trials open today (registry snapshot)](https://onco.cc/terms/colorectal-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07058012.json